Life Sciences DNA Podcast

Amar Drawid, vice president and global head of data analytics, insights, and AI for BioNTech, sits down with Nagaraja Srivatsan to discuss the evolution, adoption, and challenges of AI in the biopharma sector. He discusses the real-world implementation challenges of generative AI, the iterative process of developing business solutions, and the necessity of effective change management for organizational adoption.

Dimitris Agrafiotis, director of digital analytics and AI at Arsenal Capital Partners sits down with Nagaraja Srivatsan to discuss the current state of AI in clinical trials, the potential for AI to streamline operations, and the importance of user experience and change management in driving adoption of the technology.

Sunil Talathi, senior director and head of data insights, data sciences, and analytics for BeOne Medicines; sits down with Nagaraja Srivatsan to discuss his experience implementing AI in a biopharmaceutical company. He discusses cost considerations, prompt engineering, and the need for collaboration between humans and AI systems.

Craig Lipset, advisor and founder of Clinical Innovation Partners, sits down with Nagaraja Srivatsan to discuss how AI can bring greater predictability to clinical trials, how organizations can adopt the technology effectively, and the importance of having a culture of experimentation.

Ariel Katz, co-founder and CEO of H1, sits down with Amar Drawid to discuss how his company’s AI platform allows pharmaceutical companies to identify the right healthcare providers for their clinical trials, medical affairs, and commercial activities. He discusses the company’s unique datasets, the problem it solves for biopharmaceutical companies, and some unexpected ways the platform has been used.

Venky Iyer, director of data strategy and automation at Pfizer, sits down with Nagaraja Srivatsan to discuss the transformative role of AI and machine learning in the pharmaceutical industry. They discuss Iyer’s journey in implementing AI solutions to enhance operational efficiency at Pfizer. They talk about the importance of engaging operational teams, managing change effectively, and focusing on the value of AI adoption in improving drug development processes.

Scott Chetham, co-founder and CEO of Faro Health, sits down with Amar Drawid to discuss how AI transforms clinical trial design and drug development. He talks about how AI can enhance patient selection, feasibility assessments, and protocol writing to accelerate drug development cost-effectively.

Kannan Natarajan, senior vice president at Pfizer, discusses the potential of generative AI to streamline pharmaceutical documentation processes and improve efficiency, what he’s learned about implementing AI solutions, and the cultural challenges of adopting new technologies.

Vinod Das, Pharma R&D, Drug Innovation & AI Scouting for Bayer; sits down with Nagaraja Srivatsan to discuss the integration of generative AI in drug discovery and clinical development. He discusses the journey of AI adoption, the importance of prompt engineering, and the complexities of implementation.

Vijayalakshmi Ramshankar, professor and head of the Department of Cancer Biology and Molecular Diagnostics at Cancer Institute (WIA) sits down with Nagaraja Srivatsan to discuss the cancer research landscape in India, the work she is doing to leverage AI to improve diagnosis and outcomes, and the future of AI in oncology